ARVINAS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ARVINAS, INC. (ARVN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- ARVINAS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.90M, a 43.27% decline year-over-year.
- ARVINAS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $12.10M, a 19.33% decline year-over-year.
- ARVINAS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $8.50M, a 63.52% decline year-over-year.
- ARVINAS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $10.10M, a 59.11% decline year-over-year.
- ARVINAS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $44.00M, a 50.11% decline from fiscal 2024.
- ARVINAS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $88.20M, a 23.18% increase from fiscal 2023.
- ARVINAS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $71.60M, a 5.17% decline from fiscal 2022.
- ARVINAS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $75.50M, a 32.22% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.90M 10-Q · filed 2026-08-04 | $18.00M 10-Q · filed 2026-08-04 | $26.50M derived: sum of 3 quarters · filed 2026-08-04 | $36.60M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $12.10M 10-Q · filed 2026-05-11 | $20.60M derived: sum of 2 quarters · filed 2026-05-11 | $30.70M derived: sum of 3 quarters · filed 2026-05-11 | $41.10M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $18.60M derived: sum of 2 quarters · filed 2026-02-24 | $29.00M derived: sum of 3 quarters · filed 2026-08-04 | $44.00M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $10.10M 10-Q · filed 2025-11-05 | $20.50M derived: sum of 2 quarters · filed 2026-08-04 | $35.50M 10-Q · filed 2025-11-05 | $58.80M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $10.40M 10-Q · filed 2026-08-04 | $25.40M 10-Q · filed 2026-08-04 | $48.70M derived: sum of 3 quarters · filed 2026-08-04 | $73.40M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $15.00M 10-Q · filed 2026-05-11 | $38.30M derived: sum of 2 quarters · filed 2026-05-11 | $63.00M derived: sum of 3 quarters · filed 2026-05-11 | $84.60M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $23.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $48.00M derived: sum of 2 quarters · filed 2026-02-24 | $69.60M derived: sum of 3 quarters · filed 2026-02-24 | $88.20M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $24.70M 10-Q · filed 2025-11-05 | $46.30M derived: sum of 2 quarters · filed 2025-11-05 | $64.90M 10-Q · filed 2025-11-05 | $81.60M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $21.60M 10-Q · filed 2025-08-06 | $40.20M 10-Q · filed 2025-08-06 | $56.90M derived: sum of 3 quarters · filed 2026-02-24 | $73.60M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $18.60M 10-Q · filed 2025-05-01 | $35.30M derived: sum of 2 quarters · filed 2026-02-24 | $52.00M derived: sum of 3 quarters · filed 2026-02-24 | $70.30M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $16.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $33.40M derived: sum of 2 quarters · filed 2026-02-24 | $51.70M derived: sum of 3 quarters · filed 2026-02-24 | $71.60M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $16.70M 10-Q · filed 2024-10-30 | $35.00M derived: sum of 2 quarters · filed 2024-10-30 | $54.90M 10-Q · filed 2024-10-30 | $75.00M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-06-30 | $18.30M 10-Q · filed 2024-07-30 | $38.20M 10-Q · filed 2024-07-30 | $58.30M derived: sum of 3 quarters · filed 2025-02-11 | $77.10M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-03-31 | $19.90M 10-Q · filed 2024-05-07 | $40.00M derived: sum of 2 quarters · filed 2025-02-11 | $58.80M derived: sum of 3 quarters · filed 2025-02-11 | $78.80M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2022-12-31 | $20.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $38.90M derived: sum of 2 quarters · filed 2025-02-11 | $58.90M derived: sum of 3 quarters · filed 2025-02-11 | $75.50M 10-K · filed 2025-02-11 | ||||
| 2022-09-30 | $18.80M 10-Q · filed 2023-11-07 | $38.80M derived: sum of 2 quarters · filed 2023-11-07 | $55.40M 10-Q · filed 2023-11-07 | $72.40M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $20.00M 10-Q · filed 2023-08-08 | $36.60M 10-Q · filed 2023-08-08 | $53.60M derived: sum of 3 quarters · filed 2024-02-27 | $68.80M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $16.60M 10-Q · filed 2023-05-05 | $33.60M derived: sum of 2 quarters · filed 2024-02-27 | $48.80M derived: sum of 3 quarters · filed 2024-02-27 | $63.40M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $32.20M derived: sum of 2 quarters · filed 2024-02-27 | $46.80M derived: sum of 3 quarters · filed 2024-02-27 | $57.10M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $15.20M 10-Q · filed 2022-11-09 | $15.22M 10-Q · filed 2021-11-03 | $29.80M derived: sum of 2 quarters · filed 2022-11-09 | $40.10M 10-Q · filed 2022-11-09 | $40.12M 10-Q · filed 2021-11-03 | $48.18M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-06-30 | $14.60M 10-Q · filed 2022-08-04 | $14.57M 10-Q · filed 2021-08-05 | $24.90M 10-Q · filed 2022-08-04 | $24.90M 10-Q · filed 2021-08-05 | $32.98M derived: sum of 3 quarters · filed 2023-02-23 | $41.23M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-03-31 | $10.30M 10-Q · filed 2022-05-05 | $10.33M 10-Q · filed 2021-05-04 | $18.38M derived: sum of 2 quarters · filed 2023-02-23 | $26.63M derived: sum of 3 quarters · filed 2023-02-23 | $34.38M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | $8.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $16.33M derived: sum of 2 quarters · filed 2023-02-23 | $24.08M derived: sum of 3 quarters · filed 2023-02-23 | $30.20M 10-K · filed 2023-02-23 | $30.23M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $8.25M 10-Q · filed 2021-11-03 | $16.00M derived: sum of 2 quarters · filed 2021-11-03 | $22.12M 10-Q · filed 2021-11-03 | $27.13M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $7.75M 10-Q · filed 2021-08-05 | $13.87M 10-Q · filed 2021-08-05 | $18.88M derived: sum of 3 quarters · filed 2022-02-28 | $23.48M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $6.12M 10-Q · filed 2021-05-04 | $11.13M derived: sum of 2 quarters · filed 2022-02-28 | $15.73M derived: sum of 3 quarters · filed 2022-02-28 | $21.04M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $9.61M derived: sum of 2 quarters · filed 2022-02-28 | $14.92M derived: sum of 3 quarters · filed 2022-02-28 | $20.10M 10-K · filed 2022-02-28 | $20.07M 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $4.60M 10-Q · filed 2020-11-05 | $9.91M derived: sum of 2 quarters · filed 2020-11-05 | $15.09M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $5.31M 10-Q · filed 2020-08-04 | $10.49M 10-Q · filed 2020-08-04 | ||||||
| 2019-03-31 | $5.18M 10-Q · filed 2020-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |